Today is

Department of

Department of Internal Medicine

Photo of  Trisha Wise-Draper, MD, PhD

Trisha Wise-Draper, MD, PhD

Associate Professor of Clinical Medicine

Clinical Interest

Hematology and Oncology

Research Interests

The laboratory focuses on translational mechanisms of therapeutic resistance and biomarkers in cancer. Our main model of disease is head and neck cancer (HNC) which is the 6th most common cancer worldwide. Many treatments for HNC are toxic and result in significant morbidity. In addition, the outcomes in locally advanced HNC, especially those with high risk features and those that develop recurrence, are poor. Therefore, using patient tissue/blood samples as well as established HNC cell lines and patient derived xenograft (PDX) models, we are attempting to identify novel targets, potential biomarkers of resistance, and new treatments to lessen toxicity and improve outcomes. Specifically, we are interested in identifying mechanisms important for immunotherapy (anti-PD-1) resistance including T cell dysfunction, the role of macrophages and possible signaling pathways involved. We have already identified a couple of potential mediators that we plan to target in tissues from patients resistant to immunotherapy. We have also identified the DEK oncogene as a possible blood biomarker and immune cell stimulator in HNC patients. We are now studying possible mechanisms in which DEK is secreted into the blood and its role in cancer immune surveillance and outcome. These studies are fundamental to 1) identify patients likely to respond to particular treatment modalities for personalized medicine, 2) understanding the mechanism of immune surveillance in cancer and 3) develop new therapies that can easily be translated into phase I clinical trials.


Internal Medicine
Medical Oncology

  • BA: Miami University
  • MD/PhD: University of Cincinnati
  • Medical Degree: University of Cincinnati
  • Residency: University of Cincinnati Medical Center
Board Certifications & Licenses
  • American Board of Internal Medicine 08/06/2013
  • American Board of Internal Medicine (Medical Oncology) 10/27/2015
Contact Information
  • Vontz Center for Molecular Studies
  • 3125 Eden Avenue
  • ML 0562
  • Cincinnati, Ohio 45267
  • Office 513-558-2158
  • Fax 513-558-2124
  • Email
  • UC Institute Member Seal

Peer Reviewed Publications

Chimote, Ameet A; Hajdu, Peter; Sfyris, Alexandros M; Gleich, Brittany N; Wise-Draper, Trisha; Casper, Keith A; Conforti, Laura 2017. Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. Cancer research, 77 1, 53-61

Wise-Draper, Trisha M; Moorthy, Ganesh; Salkeni, Mohamad A; Karim, Nagla Abdel; Thomas, Hala Elnakat; Mercer, Carol A; Beg, M Shalaan; O'Gara, Sue; Olowokure, Olugbenga; Fathallah, Hassana; Kozma, Sara C; Thomas, George; Rixe, Olivier; Desai, Pankaj; Morris, John C 2017. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Targeted oncology, 12 3, 323-332

Riaz, Muhammad Kashif; Bal, Susan; Wise-Draper, Trisha 2016. The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. Journal of surgical oncology, ,

Adams, A K; Hallenbeck, G E; Casper, K A; Patil, Y J; Wilson, K M; Kimple, R J; Lambert, P F; Witte, D P; Xiao, W; Gillison, M L; Wikenheiser-Brokamp, K A; Wise-Draper, T M; Wells, S I 2015. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. Oncogene, 34 7, 868-77

Malhotra, Akshiv; Sendilnathan, Arun; Old, Matthew O; Wise-Draper, Trisha M 2015. Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic virotherapy, 4 , 83-93

Pease, Nicholas A; Wise-Draper, Trisha; Privette Vinnedge, Lisa 2015. Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer. Journal of oncology, 2015 , 106517

Adams, Allie K; Wise-Draper, Trisha M; Wells, Susanne I 2014. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers, 6 3, 1793-820

Ghose, Abhimanyu; Yellu, Mahender; Wise-Draper, Trisha; Sharma, Divya; Qualtieri, Julianne; Latif, Tahir; Medlin, Stephen 2014. Lymphoma presenting as secondary HLH: a review with a tale of two cases. Clinical lymphoma, myeloma & leukemia, 14 6, e187-93

Bahassi, El Mustapha; Li, Ya-Qin; Wise-Draper, Trisha M; Deng, Li; Wang, Jiang; Darnell, Colleen N; Wilson, Keith M; Wells, Susanne I; Stambrook, Peter J; Rixe, Olivier 2013. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. European journal of cancer (Oxford, England : 1990), 49 10, 2345-55

Wise-Draper, Trisha M; Draper, David J; Gutkind, J Silvio; Molinolo, Alfredo A; Wikenheiser-Brokamp, Kathryn A; Wells, Susanne I 2012. Future directions and treatment strategies for head and neck squamous cell carcinomas. Translational research : the journal of laboratory and clinical medicine, 160 3, 167-77

Kavanaugh, Gina M; Wise-Draper, Trisha M; Morreale, Richard J; Morrison, Monique A; Gole, Boris; Schwemberger, Sandy; Tichy, Elisia D; Lu, Lu; Babcock, George F; Wells, James M; Drissi, Rachid; Bissler, John J; Stambrook, Peter J; Andreassen, Paul R; Wiesmüller, Lisa; Wells, Susanne I 2011. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic acids research, 39 17, 7465-76

Wise-Draper, Trisha M; Mintz-Cole, Rachael A; Morris, Teresa A; Simpson, David S; Wikenheiser-Brokamp, Kathryn A; Currier, Mark A; Cripe, Timothy P; Grosveld, Gerard C; Wells, Susanne I 2009. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer research, 69 5, 1792-9

Wise-Draper, Trisha M; Morreale, Richard J; Morris, Teresa A; Mintz-Cole, Rachael A; Hoskins, Elizabeth E; Balsitis, Scott J; Husseinzadeh, Nader; Witte, David P; Wikenheiser-Brokamp, Kathryn A; Lambert, Paul F; Wells, Susanne I 2009. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. The American journal of pathology, 174 1, 71-81

Hoskins, E E; Gunawardena, R W; Habash, K B; Wise-Draper, T M; Jansen, M; Knudsen, E S; Wells, S I 2008. Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway. Oncogene, 27 35, 4798-808

Wise-Draper, Trisha M; Wells, Susanne I 2008. Papillomavirus E6 and E7 proteins and their cellular targets. Frontiers in bioscience : a journal and virtual library, 13 , 1003-17

Wise-Draper, Trisha M; Allen, Hillary V; Jones, Elizabeth E; Habash, Kristen B; Matsuo, Hiroshi; Wells, Susanne I 2006. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Molecular and cellular biology, 26 20, 7506-19

Wise-Draper, Trisha M; Allen, Hillary V; Thobe, Megan N; Jones, Elizabeth E; Habash, Kristen B; Münger, Karl; Wells, Susanne I 2005. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. Journal of virology, 79 22, 14309-17

Abstract Publications

Adams, A.K., Hallenbeck, G.E., Casper, K.A., Patil, Y.J., Wilson, K.M., Kimple, R.J., Lambert, P.F., Witte, D.P., Xiao, W., Gillison, M.L., Wise-Draper T.M., and Wikenheiser-Brokamp, K.A. 2015. DEK promotes HPV-positive and-negative head and neck cancer cell proliferation Oncogene, 34(7) , 868

Pease, N.A., Wise-Draper, T. and Privette Vinnedge, L. 2015. Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer Journal of oncology, ,

Wise-Draper, T.M., Mintz-Cole, R.A., Morris, T.A., Simpson, D.S., Wikenheiser-Brokamp, K.A., Currier, M.A., Cripe, T.P., Grosveld, G.C. and Wells, S.I. 2009. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo Cancer research, 69(5) , 1792